These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

144 related articles for article (PubMed ID: 35973753)

  • 1. Bictegravir/emtricitabine/tenofovir alafenamide in patients with genotypic NRTI resistance.
    Shafran SD; Hughes CA
    HIV Med; 2023 Mar; 24(3):361-365. PubMed ID: 35973753
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide (B/F/TAF) From Dolutegravir (DTG)+F/TAF or DTG+F/Tenofovir Disoproxil Fumarate (TDF) in the Presence of Pre-existing NRTI Resistance.
    Acosta RK; Willkom M; Andreatta K; Liu H; Martin R; Parvangada A; Martin H; Collins S; White KL
    J Acquir Immune Defic Syndr; 2020 Nov; 85(3):363-371. PubMed ID: 32701823
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Impact of preexisting nucleos(t)ide reverse transcriptase inhibitor resistance on the effectiveness of bictegravir/emtricitabine/tenofovir alafenamide in treatment experience patients.
    Micán R; de Gea Grela A; Cadiñanos J; de Miguel R; Busca C; Bernardino JI; Valencia E; Montes ML; Montejano R; Moreno V; Pérez Valero I; Serrano L; González-García J; Arribas JR; Martín-Carbonero L
    AIDS; 2022 Nov; 36(14):1941-1947. PubMed ID: 35848506
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD Trials.
    Lathouwers E; Wong EY; Brown K; Baugh B; Ghys A; Jezorwski J; Mohsine EG; Van Landuyt E; Opsomer M; De Meyer S;
    AIDS Res Hum Retroviruses; 2020 Jan; 36(1):48-57. PubMed ID: 31516033
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Rare emergence of drug resistance in HIV-1 treatment-naïve patients after 48 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide.
    Margot NA; Kitrinos KM; Fordyce M; McCallister S; Miller MD; Callebaut C
    HIV Clin Trials; 2016 Mar; 17(2):78-87. PubMed ID: 26892863
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Switching to Bictegravir, Emtricitabine, and Tenofovir Alafenamide in Virologically Suppressed Adults With Human Immunodeficiency Virus.
    Sax PE; Rockstroh JK; Luetkemeyer AF; Yazdanpanah Y; Ward D; Trottier B; Rieger A; Liu H; Acosta R; Collins SE; Brainard DM; Martin H;
    Clin Infect Dis; 2021 Jul; 73(2):e485-e493. PubMed ID: 32668455
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of NRTI resistance mutations on virological effectiveness of antiretroviral regimens containing elvitegravir: a multi-cohort study.
    Modica S; Redi D; Gagliardini R; Giombini E; Bezenchek A; Di Carlo D; Maggiolo F; Lombardi F; Borghetti A; Farinacci D; Callegaro A; Gismondo MR; Colafigli M; Sterrantino G; Costantini A; Ferrara SM; Rusconi S; Zazzi M; Rossetti B; De Luca A; Gianotti N
    J Antimicrob Chemother; 2020 Jan; 75(1):194-199. PubMed ID: 31605107
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Rare emergence of drug resistance in HIV-1 treatment-naïve patients receiving elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide for 144 weeks.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    J Clin Virol; 2018 Jun; 103():37-42. PubMed ID: 29627709
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase IV randomised, open-label pilot study to evaluate switching from protease-inhibitor based regimen to Bictegravir/Emtricitabine/Tenofovir Alafenamide single tablet regimen in Integrase inhibitor-naïve, virologically suppressed HIV-1 infected adults harbouring drug resistance mutations (PIBIK study): study protocol for a randomised trial.
    Iwuji CC; Churchill D; Bremner S; Perry N; To Y; Lambert D; Bruce C; Waters L; Orkin C; Geretti AM
    BMC Infect Dis; 2020 Jul; 20(1):524. PubMed ID: 32689975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Switching to Bictegravir/Emtricitabine/Tenofovir Alafenamide in Black Americans With HIV-1: A Randomized Phase 3b, Multicenter, Open-Label Study.
    Hagins D; Kumar P; Saag M; Wurapa AK; Brar I; Berger D; Osiyemi O; Hileman CO; Ramgopal MN; McDonald C; Blair C; Andreatta K; Collins SE; Brainard DM; Martin H;
    J Acquir Immune Defic Syndr; 2021 Sep; 88(1):86-95. PubMed ID: 34397746
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Switching to bictegravir/emtricitabine/tenofovir alafenamide maintained HIV-1 RNA suppression in participants with archived antiretroviral resistance including M184V/I.
    Andreatta K; Willkom M; Martin R; Chang S; Wei L; Liu H; Liu YP; Graham H; Quirk E; Martin H; White KL
    J Antimicrob Chemother; 2019 Dec; 74(12):3555-3564. PubMed ID: 31430369
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Effectiveness of second-generation integrase strand-transfer inhibitor-based regimens for antiretroviral-experienced people with HIV who had viral rebound.
    Chen GJ; Sun HY; Chang SY; Hsieh SM; Sheng WH; Chuang YC; Huang YS; Lin KY; Liu WC; Su YC; Hung CC
    J Microbiol Immunol Infect; 2023 Oct; 56(5):988-995. PubMed ID: 37574435
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Week 96 resistance analyses of the once-daily, single-tablet regimen (STR) darunavir/cobicistat/emtricitabine/tenofovir alafenamide (D/C/F/TAF) in adults living with HIV-1 from the phase 3 randomized AMBER and EMERALD trials.
    Lathouwers E; Weinsteiger S; Baugh B; Ghys A; Jezorwski J; Mohsine EG; Van Landuyt E; De Meyer S
    J Med Virol; 2021 Jun; 93(6):3985-3990. PubMed ID: 33300183
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Infrequent development of drug resistance in HIV-1-infected treatment-naive subjects after 96 weeks of treatment with elvitegravir/cobicistat/emtricitabine/tenofovir alafenamide or elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate.
    Margot N; Cox S; Das M; McCallister S; Miller MD; Callebaut C
    Antivir Ther; 2017; 22(5):443-446. PubMed ID: 28076335
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High efficacy of switching to bictegravir/emtricitabine/tenofovir alafenamide in people with suppressed HIV and preexisting M184V/I.
    Sax PE; Andreatta K; Molina JM; Daar ES; Hagins D; Acosta R; D'Antoni ML; Chang S; Martin R; Liu H; Blair C; McNicholl I; Gallant J; Collins SE; Martin H; White KL
    AIDS; 2022 Sep; 36(11):1511-1520. PubMed ID: 35466963
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Bictegravir/emtricitabine/tenofovir alafenamide ensures high rates of virological suppression maintenance despite previous resistance in PLWH who optimize treatment in clinical practice.
    Armenia D; Forbici F; Bertoli A; Berno G; Malagnino V; Gagliardini R; Borghi V; Gennari W; Cicalini S; Buonomini A; Teti E; Lanini S; Latini A; Sarmati L; Mussini C; Andreoni M; Antinori A; Perno CF; Ceccherini-Silberstein F; Santoro MM
    J Glob Antimicrob Resist; 2022 Sep; 30():326-334. PubMed ID: 35793776
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Three-year study of pre-existing drug resistance substitutions and efficacy of bictegravir/emtricitabine/tenofovir alafenamide in HIV-1 treatment-naive participants.
    Acosta RK; Chen GQ; Chang S; Martin R; Wang X; Huang H; Brainard D; Collins SE; Martin H; White KL
    J Antimicrob Chemother; 2021 Jul; 76(8):2153-2157. PubMed ID: 33880558
    [TBL] [Abstract][Full Text] [Related]  

  • 18. HIV multi-drug resistance at first-line antiretroviral failure and subsequent virological response in Asia.
    Jiamsakul A; Sungkanuparph S; Law M; Kantor R; Praparattanapan J; Li PC; Phanuphak P; Merati T; Ratanasuwan W; Lee CK; Ditangco R; Mustafa M; Singtoroj T; Kiertiburanakul S;
    J Int AIDS Soc; 2014; 17(1):19053. PubMed ID: 25141905
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Bictegravir, emtricitabine, and tenofovir alafenamide versus dolutegravir, abacavir, and lamivudine for initial treatment of HIV-1 infection (GS-US-380-1489): a double-blind, multicentre, phase 3, randomised controlled non-inferiority trial.
    Gallant J; Lazzarin A; Mills A; Orkin C; Podzamczer D; Tebas P; Girard PM; Brar I; Daar ES; Wohl D; Rockstroh J; Wei X; Custodio J; White K; Martin H; Cheng A; Quirk E
    Lancet; 2017 Nov; 390(10107):2063-2072. PubMed ID: 28867497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Increased viral load in a hospitalized patient on treatment with crushed bictegravir/emtricitabine/tenofovir alafenamide: A case report and review of the literature.
    Rowe SM; Clary JC; Drummond M; Derrick C; Sanasi K; Bookstaver PB
    Am J Health Syst Pharm; 2022 Aug; 79(16):1330-1336. PubMed ID: 35511892
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.